About: OBJECTIVES: Coagulopathy is one of the characteristics of critically ill patients with Coronavirus Disease 2019 (COVID‐19). Antiphospholipid antibodies (aPLs) contribute to coagulopathy, but their role in COVID‐19 remains unclear. We aimed to determine the prevalence and characteristics of aPLs in patients with COVID‐19. METHODS: Sera collected from 66 critically ill and 13 non‐critically ill patients with COVID‐19 were tested for anti‐cardiolipin (aCL) and anti‐β2‐glycoprotein 1 (aβ2GP1) (IgG, IgM, and IgA) and IgG aβ2GP1‐D1 by the chemiluminescence assay (CIA) and IgM and IgG anti‐phosphatidylserine/prothrombin (aPS/PT) by ELISA. RESULTS: aPLs were detected in 47.0% of critically ill patients (31/66), but not in patients with non‐critical conditions. IgA aβ2GP1 was the most common aPL, present in 28.8% (19/66) critically ill patients, followed by IgA aCL (25.8%,17/66) and IgG aβ2GP1 (18.2%,12/66). For multiple aPLs, IgA aβ2GP1+IgA aCL was the most common type (22.7%, 15/66), followed by IgA aβ2GP1+IgA aCL+ IgG aβ2GP1 (15.2%, 10/66). aPLs emerge around 35‐39 days post‐disease onset. Dynamic analysis of aPLs revealed 4 patterns based on persistence or transient appearance of the aPLs. Patients with multiple aPLs displayed significantly higher incidence of cerebral infarction (p=0.023). CONCLUSIONS: aPLs were common in critically ill patients. Multiple medium or high levels aPLs may help identify patients at risk of developing cerebral infarction. aPLs may be transient and disappear within a few weeks, but in genetically predisposed patients, COVID‐19 may trigger the development of “COVID‐19‐induced‐APS‐like‐syndrome”. Long‐term follow‐up on COVID‐19 patients positive for aPLs would be of great importance.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : fabio:Abstract, within Data Space : covidontheweb.inria.fr associated with source document(s)

AttributesValues
type
value
  • OBJECTIVES: Coagulopathy is one of the characteristics of critically ill patients with Coronavirus Disease 2019 (COVID‐19). Antiphospholipid antibodies (aPLs) contribute to coagulopathy, but their role in COVID‐19 remains unclear. We aimed to determine the prevalence and characteristics of aPLs in patients with COVID‐19. METHODS: Sera collected from 66 critically ill and 13 non‐critically ill patients with COVID‐19 were tested for anti‐cardiolipin (aCL) and anti‐β2‐glycoprotein 1 (aβ2GP1) (IgG, IgM, and IgA) and IgG aβ2GP1‐D1 by the chemiluminescence assay (CIA) and IgM and IgG anti‐phosphatidylserine/prothrombin (aPS/PT) by ELISA. RESULTS: aPLs were detected in 47.0% of critically ill patients (31/66), but not in patients with non‐critical conditions. IgA aβ2GP1 was the most common aPL, present in 28.8% (19/66) critically ill patients, followed by IgA aCL (25.8%,17/66) and IgG aβ2GP1 (18.2%,12/66). For multiple aPLs, IgA aβ2GP1+IgA aCL was the most common type (22.7%, 15/66), followed by IgA aβ2GP1+IgA aCL+ IgG aβ2GP1 (15.2%, 10/66). aPLs emerge around 35‐39 days post‐disease onset. Dynamic analysis of aPLs revealed 4 patterns based on persistence or transient appearance of the aPLs. Patients with multiple aPLs displayed significantly higher incidence of cerebral infarction (p=0.023). CONCLUSIONS: aPLs were common in critically ill patients. Multiple medium or high levels aPLs may help identify patients at risk of developing cerebral infarction. aPLs may be transient and disappear within a few weeks, but in genetically predisposed patients, COVID‐19 may trigger the development of “COVID‐19‐induced‐APS‐like‐syndrome”. Long‐term follow‐up on COVID‐19 patients positive for aPLs would be of great importance.
subject
  • Zoonoses
  • Autoimmune diseases
  • Rheumatology
  • Viral respiratory tract infections
  • COVID-19
  • Coagulopathies
  • Occupational safety and health
  • Emergency life support
  • Emergency medicine courses
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software